Hematopoietic cell transplantation in the treatment of leukemia.

Semin Oncol Nurs

Stem Cell Transplantation/Leukemia and Lymphoma, Services, Barnes Jewish Hospital, Mailstop 90-01069, 216 S. Kingshighway Blvd, St Louis, MO 63108, USA.

Published: May 2003

Objectives: To review the current evidence regarding the role and benefits of hematopoietic cell transplantation (HCT) in leukemia.

Data Sources: Review articles, original articles, internet web sites, and books.

Conclusion: HCT is a potentially curative treatment modality for patients with hematologic malignancies such as leukemia.

Implications For Nursing Practice: Nurses working with patients undergoing HCT need awareness of the type of leukemia, source of the hematopoietic cell product, type of preparative regimen used, and the complications of the procedure will enable nurses to educate and intervene with patients and their family members throughout the transplant trajectory.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0749-2081(03)00008-1DOI Listing

Publication Analysis

Top Keywords

hematopoietic cell
12
cell transplantation
8
transplantation treatment
4
treatment leukemia
4
leukemia objectives
4
objectives review
4
review current
4
current evidence
4
evidence role
4
role benefits
4

Similar Publications

The BMT CTN 1703 phase III trial confirmed that graft-versus-host disease (GVHD) prophylaxis with post-transplantation cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF) results in superior GVHD-free, relapse-free survival (GRFS) compared with Tac/methotrexate (MTX) prophylaxis. This companion study assesses the effect of these regimens on patient-reported outcomes (PROs). Using the Lee Chronic GVHD Symptom Score and PROMIS subscales (physical function, GI symptoms, social role satisfaction) as primary end points and hemorrhagic cystitis symptoms and Lee subscales as secondary end points, responses from English and Spanish speakers were analyzed at baseline and days 100, 180, and 365 after transplant.

View Article and Find Full Text PDF

Chronic low-grade inflammation observed in older adults, termed inflammaging, is a common feature underlying a multitude of aging-associated maladies including a decline in hematopoietic activity. However, whether suppression of inflammaging can preserve hematopoietic health span remains unclear, in part because of a lack of tools to measure inflammaging within hematopoietic stem cells (HSCs). Here, we identify thrombospondin-1 (Thbs1) as an essential regulator of inflammaging within HSCs.

View Article and Find Full Text PDF

Mitochondrial DNA (mtDNA) is highly polymorphic, and host mtDNA variation has been associated with altered cancer severity. To determine the basis of this mtDNA-cancer association, we analyzed conplastic mice with the C57BL/6J (B6) nucleus but two naturally occurring mtDNA lineages, and , where mitochondria generate more oxidative phosphorylation (OXPHOS)-derived reactive oxygen species (mROS). In a cardiac transplant model, Foxp3+ T regulatory (Treg) cells supported long-term allograft survival, whereas Treg cells failed to suppress host T effector (Teff) cells, leading to acute rejection.

View Article and Find Full Text PDF

Monocyte-cancer cell fusion is mediated by phosphatidylserine-CD36 receptor interaction and induced by ionizing radiation.

PLoS One

January 2025

Division of Cell- and Neurobiology, Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden.

Emerging evidence suggests that fusion of cancer cells with leucocytes, such as macrophages, plays a significant role in cancer metastasis and results in tumor hybrid cells that acquire resistance to chemo- and radiation therapy. However, the precise mechanisms behind the leukocyte-cancer cell fusion remain unclear. The present in vitro study explores the presence of fusion between the monocyte cell line (THP-1) and the breast cancer cell line (MCF-7) in relation to the expression of CD36 and phosphatidylserine with and without treatment of these cells with ionizing radiation.

View Article and Find Full Text PDF

Early neutrophil activation and NETs release in the pristane-induced lupus mice model.

PLoS One

January 2025

Laboratório de Imunologia Celular (LIM-17), Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.

Background: NETosis is recognized as an important source of autoantigens. Therefore, we hypothesized whether the pristane-induced lupus mice model shows early activation of neutrophils, the presence of low-density granulocytes (LDGs), and neutrophil extracellular traps (NETs) release, which could contribute to the development of a lupus phenotype.

Methods: Twelve female wild-type Balb/c mice were intraperitoneally injected with pristane (n = 6; pristane group) or saline (n = 6; control group).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!